Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Biosimulation Market Forecast: What Value Will The Market Reach By 2030?
The biosimulation market has experienced substantial expansion in recent years. Its valuation is set to increase from $4.98 billion in 2025 to $5.84 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.3%. This historical development can be ascribed to several factors, including the surge in pharmaceutical R&D endeavors, the escalating intricacy of biological systems research, the incorporation of computational modeling into drug development processes, the growing regulatory approval of simulation data, and the accessibility of advanced computing infrastructure.
The biosimulation market size is anticipated to undergo significant expansion over the next few years. It is projected to reach $11.11 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 17.5%. This expansion during the forecast period is primarily driven by factors such as the escalating demand for precision medicine modeling, increasing investments in AI-driven biosimulation tools, the broader scope of in silico clinical trials, a growing emphasis on reducing drug development timelines, and the wider adoption of cloud-based biosimulation platforms. Furthermore, prominent trends expected during this period include the rising acceptance of model-based drug development, enhanced utilization of PK and PD simulation platforms, the increasing integration of virtual clinical trials, the expansion of disease modeling applications, and a strengthened focus on predictive toxicology modeling.
Get A Free Sample Report With In-Depth Market Insights:
Biosimulation Market Demand Drivers: What’s Powering Industry Growth?
Global increases in healthcare spending are projected to fuel the expansion of the biosimulation market throughout the forecast period. This expenditure encompasses the entire sum of resources allocated to healthcare products and services, such as the creation of new drugs, clinical studies, and advancements in medical technology. Factors contributing to this rise in spending include an increasing demand for sophisticated medical therapies, the global aging demographic, and heightened investments in developing innovative pharmaceuticals. The biosimulation market directly profits from this trend, as greater spending hastens the integration of computational modeling and simulation instruments, facilitating virtual clinical trials and predictive disease modeling for pharmaceutical advancement. As an illustration, the American Medical Association, a US-based national professional association, reported in April 2025 that health-care spending reached US$ 4.87 trillion in 2023, representing a 7.5% year-on-year increase, which translated to approximately US$ 14,570 per individual. Consequently, the global increase in healthcare expenditure is a primary driver for the expansion of the biosimulation market.
Biosimulation Market Segment Analysis And Revenue Potential
The biosimulation market covered in this report is segmented –
1) By Product: Software, Services
2) By Application: Drug Development, Drug Discovery, Other Applications
3) By End User: Pharmaceutical And Biotechnology Companies, Contract Research Organizations (CROs), Academic Research Institutions, Other End Users
Subsegments:
1) By Software: Pharmacokinetics (PK) Simulation Software, Pharmacodynamics (PD) Simulation Software, Toxicology Simulation Software, Disease Modeling Software, Integrated Biosimulation Platforms
2) By Services: Consulting Services, Model Development Services, Data Analysis And Interpretation Services, Training And Support Services, Custom Simulation Services
Biosimulation Market Trends Redefining Industry Growth
Leading firms within the biosimulation market are concentrating on creating sophisticated solutions, such as integrated pharmacokinetic-pharmacodynamic (PK-PD) modeling platforms. These innovations aim to boost drug development efficiency, refine predictive accuracy, and accelerate therapeutic decision-making. Integrated PK-PD modeling platforms are essentially software systems designed to simulate drug behavior and effects in virtual populations, thereby enabling researchers to optimize dosing, predict outcomes, and reduce reliance on costly clinical trials. As an illustration, Certara, Inc, a US-based biosimulation and drug development company, introduced Phoenix version 8.5 in August 2024. This advanced platform specifically streamlines PK-PD modeling, population simulations, and clinical trial predictions. The software equips researchers with enhanced data analysis, visualization tools, and scenario testing to improve decision-making throughout the drug development process. By leveraging these biosimulation capabilities, this initiative supports the faster, safer, and more cost-effective development of new therapies, simultaneously optimizing clinical study design.
Biosimulation Market Key Players Shaping Industry Direction
Major companies operating in the biosimulation market are Certara Inc.; Dassault Systèmes SE; Schrödinger Inc.; Simulations Plus Inc.; Rhenovia Pharma SAS; Insilico Biotechnology AG; Genedata AG; Entelos Inc.; Physiomics plc; Rosa & Co. LLC.; In Silico Biosciences Inc.; INOSIM Software GmbH; LeadInvent Technologies Limited; Nuventra Pharma Sciences Inc.; Archimedes Inc.; VeriSIM Life Inc.; Compugen Inc.; Leadscope Inc.; Pharmaceutical Product Development LLC; Advanced Chemistry Development Inc.; Chemical Computing Group Inc.; Immunetrics and PPD Inc.; Instem India Private Limited; Evidera Inc.; Biomodels LLC; PhysioStim SA; Lhasa Limited; SimBioSys Inc.; Cadence Design Systems Inc.; Allucent Inc.
View The Full Biosimulation Market Report:
Biosimulation Market Top Region By Revenue And Market Share
North America was the largest region in the biosimulation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimulation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.
